The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...
New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -...
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral disea...
Nxera Pharma Co – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Bi...
Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, announced that the M...
Nucala is the first and only biologic in Japan with a four-weekly dosing schedule for this condition Chronic rhinosinusitis with nasal polyps (CRSwNP)...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd , announced that the Company has sign...
Fujitsu announced that it will begin initiatives to attract global clinical trials to Japan and tackle the 'drug loss' issue by working with pharmaceutic...
Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...
NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria...
Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sanky...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with met...
Nxera Pharma announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neur...
© 2024 Biopharma Boardroom. All Rights Reserved.
